Researchers identify pathway behind MASLD-linked mutation
A study showed that a genetic mutation associated with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, results in an…
News
American Liver Foundation gala to recognize biliary atresia family
The American Liver Foundation (ALF) is granting its Spirit of Giving Family Award to a U.S. family for its dedication to raising funds and…
Study offers insights into potential for vaccine for hepatitis C
Researchers have uncovered the structure of the protein complex that allows the hepatitis C virus (HCV) to infect human cells, allowing them to reproduce and…
Advanz gets suspension of decision to revoke Ocaliva EU approval
Advanz Pharma has secured a temporary suspension of a decision by the European Commission (EC) to revoke conditional approval of Ocaliva (obeticholic acid) for…
New PLEC gene mutations are likely cause of girls’ liver ailment PFIC
Scientists in Thailand have identified four new mutations in the PLEC gene as the likely cause of progressive familial intrahepatic cholestasis (PFIC) in two…
Nonprofit’s petition aims to expedite Canadian access to Rezdiffra
The Fatty Liver Alliance, a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian…
Liver disorder most common Alagille symptom in children
Cholestasis, where the flow of the digestive fluid bile from the liver to the intestines slows or stalls, is the most common feature across…
Study details antiviral mechanisms of Atea treatment for hepatitis C
Researchers have detailed exactly how bemnifosbuvir — part of Atea Pharmaceuticals’ antiviral treatment combination for chronic hepatitis C infections — turns into the…
Organizations plan activities, events for PBC Awareness Month
September will be a busy month for the primary biliary cholangitis (PBC) community as organizations advocate for better patient care through conferences, walks, and…
Methylprednisolone reduces liver damage signs in cholestasis infantsÂ
Two weeks of oral methylprednisolone twice a day as an add-therapy significantly lowered signs of liver damage and inflammation among infants with cholestasis, a…
Recent Posts
- Awareness month focuses on challenges for rural communities
- My son’s fourth birthday is yet another milestone to celebrate
- Weight loss surgery may protect liver with MASH-related cirrhosis
- Livmarli relieves itch in adolescents with Alagille syndrome: Analysis
- HBV vaccine birth dose not tied to premature babies’ lung disease risk